Prion removal by nanofiltration under different experimental conditions

Biologicals

Volumn 36, Issue 1, 2008, Pages 27-36

  Yunoki, Mikihiro ^a,b   Tanaka, Hiroyuki ^b   Urayama, Takeru ^a,b   Hattori, Shinji ^b   Ohtani, Masahiro ^b   Ohkubo, Yuji ^b   Kawabata, Yoshiyasu ^b   Miyatake, Yuuki ^b   Nanjo, Ayako ^b   Iwao, Eiji ^c   Morita, Masanori ^b   Wilson, Elaine ^d   MacLean, Christine ^d   Ikuta, Kazuyoshi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Benesis Corporation   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^d Invitrogen BioServices ^*  (United Kingdom)

Author keywords

Clearance study; Filter; Prion; Removal; Spike material

Indexed keywords

PRION PROTEIN;

ARTICLE; FILTER; NANOFILTRATION; PARTICLE SIZE; PRIORITY JOURNAL; ULTRASOUND; WESTERN BLOTTING;

ANIMALS; CRICETINAE; FILTRATION; NANOSTRUCTURES; NANOTECHNOLOGY; PARTICLE SIZE; PRIONS;

CRICETINAE; SCRAPIE PRION;

EID: 38449096582     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2007.04.005     Document Type: Article

References (22)

1. Health Protection Agency. Fourth case of variant CJD infection associated with blood transfusion. Press release (18 January, 2007). http://www.hpa.org.uk/hpa/news/articles/press_releases/2007/070118_vCJD. htm
2. Castilla J., Saá P., and Soto C. Detection of prions in blood. Nature medicine 11 9 (2005) 982-985
3. European Medicines Agency/The Committee for Medicinal Products for Human Use (CHMP)/Biotechnology Working Party. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMEA/CPMP/BWP/2879/02/rev 1. London (23 June, 2004). http://www.emea.europa.eu/pdfs/human/press/pos/287902rev1.pdf
4. The European Agency for the Evaluation of Medicinal Products/The Committee for Medicinal Products for Human Use (CHMP)/Biotechnology Working Party. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. CPMP/BWP/5136/03 London (21 October, 2004). http://www.emea.europa.eu/pdfs/human/bwp/513603en.pdf
5. Strengthening of quality and safety assurance of drugs and medical devices manufactured using components of human origin as raw materials. PFSB notification no.0209003 dated February 9, 2005; Japan: MHLW (in Japanese).
6. Stenland C.J., Lee D.C., Brown P., Petteway Jr. S.R., and Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 42 11 (2002) 1497-1500
7. Vey M., Baron H., Weimer T., and Gröner A. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 30 3 (2002) 187-196
8. Foster P.R. Removal of TSE agents from blood products. Vox Sang 87 S2 (2004) 7-10
9. Tateishi J., Kitamoto T., Ishikawa G., and Manabe S. Removal of causative agent of Creutzfeldt-Jakob disease (CJD) through membrane filtration method. Membrane 18 6 (1993) 357-362
10. ® virus removal filters. Biologicals 29 1 (2001) 17-25
11. Van Holten W.R., Autenrieth S., Boose J.A., Hsieh W.T., and Dolan S. Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter. Transfusion 42 8 (2002) 999-1004
12. Kimberlin R.H., and Walker C.A. Characteristics of a short incubation model of scrapie in the golden hamster. J Gen Virol 34 2 (1977) 295-304
13. Kascsak R.J., Rubenstein R., Merz P.A., Tonna-DeMasi M., Fersko R., Carp R.I., et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61 12 (1987) 3688-3693
14. Lee D.C., Stenland C.J., Hartwell R.C., Ford E.K., Cai K., Miller J.L.C., et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of prion protein. J Virol Methods 84 1 (2000) 77-89
15. Fraser H., and Dickinson A.G. The sequential development of the brain lesions of scrapie in three strains of mice. J Comp Pathol 78 3 (1968) 301-311
16. Kärber J. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmak 162 (1931) 480-483
17. Somerville R.A., and Carp R.I. Altered scrapie infectivity estimates by titration and incubation period in the presence of detergents. J Gen Virol 64 9 (1983) 2045-2050
18. Taylor D.M., and Fernie K. Exposure to autoclaving or sodium hydroxide extends the dose-response curve of the 263K strain of scrapie agent in hamsters. J Gen Virol 77 4 (1996) 811-813
19. Sc by cathepsin D does not reduce prion infectivity. Biochem J 395 (2006) 443-448
20. Trifilo M.J., Yajima T., Gu Y., Dalton N., Peterson K.L., Race R.E., et al. Prion-induced amyloid heart disease with high blood infectivity in transgenic mice. Science 313 5783 (2006) 94-97
21. Silveira R.J., Raymond J.G., Hughson G.A., Race E.R., Sim L.V., Hayes F.S., et al. The most infectious prion protein particles. Nature 437 7056 (2005) 257-261
22. Yunoki M., Urayama T., and Ikuta K. Possible removal of prion agents from blood products during the manufacturing processes. Future Virol 1 5 (2006) 659-674